(COYA) Coya Therapeutics, Inc. Business Model Canvas Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(COYA) Coya Therapeutics, Inc. Complete Analysis Pack
Coya Therapeutics Business Model Canvas: Strategy to Value
Explore Coya Therapeutics, Inc.’s Business Model Canvas to see how it translates a focused biotech strategy into value creation. This concise, research-ready snapshot highlights key partners, revenue logic, and the activities that support its pipeline. Get the full canvas for deeper strategic insight and a sharper view of the opportunity.
Partnerships
Clinical neurology trial sites
Clinical neurology trial sites are key partners for Coya Therapeutics, Inc. because COYA 101 already completed a Phase 2a ALS study, and specialist centers handled patient enrollment, protocol visits, and safety and efficacy data collection. These same sites are also needed for IND work and later trials of COYA 301 and COYA 302, where ALS care demands tight neurologist oversight and repeated clinical scoring.
CRO and clinical operations vendors
Coya Therapeutics, Inc. relies on CRO and clinical operations vendors to run multi-site trials, handling monitoring, data management, and site coordination. That outsourced model lets Coya scale development fast without hiring every function in-house, which is standard for a clinical-stage biotech with limited internal headcount and cash discipline.
CDMO and manufacturing partners
Coya Therapeutics, Inc. depends on CDMO and manufacturing partners because COYA 101 is an autologous cell therapy, so each patient batch needs specialized, small-scale production, release testing, and cold-chain control. COYA 301 and COYA 302 also need biologics development and CMC execution before IND filing, and these 3 pipeline programs make partner quality and capacity a key operating risk.
CDMOs help Coya Therapeutics, Inc. move from process development to GMP supply readiness, which matters when IND advancement depends on reproducible manufacturing data and tested release specs.
Academic and scientific collaborators
Academic and scientific collaborators help Coya Therapeutics, Inc. move its Treg platform from lab data to human proof, especially in ALS, FTD, autoimmune, and metabolic disease. These links are valuable because ALS affects about 30,000 people in the U.S., so fast translational work and biomarker validation can shape both trial design and scientific credibility.
- Supports translational research
- Strengthens preclinical models
- Validates biomarkers and targets
- Spans ALS, FTD, autoimmune, metabolic
Regulatory and advisory stakeholders
Coya Therapeutics, Inc. depends on FDA and ethics-board partners during IND-enabling work, because first-in-human studies can’t start until the nonclinical package, CMC data, and protocol are cleared. External regulatory advisers help tune safety, dosing, and filing strategy for novel Treg-derived exosomes and combination biologics, where the FDA still expects a strong risk package and close sponsor oversight.
- FDA and ethics review gate human trials.
- Advisers shape safety and filing plans.
- Key for novel exosomes and combo biologics.
How Coya’s Partners Power Its ALS Cell Therapy Pipeline
Coya Therapeutics, Inc. relies on neurology trial sites, CROs, CDMOs, and academic partners to move COYA 101, COYA 301, and COYA 302 through IND work and clinical testing. That matters in ALS, which affects about 30,000 people in the U.S., because specialist sites and GMP manufacturing are needed for patient enrollment, safety checks, and repeatable cell-therapy supply.
| Partner | Role | Why it matters |
|---|---|---|
| Trial sites | Enroll and assess patients | ALS expertise |
| CROs/CDMOs | Run studies and make batches | Scale and GMP control |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Coya Therapeutics, Inc. aligned to its neuroinflammation therapy strategy, investor use, and core 9-block framework.
Customizable Excel Spreadsheet
Quickly spot Coya Therapeutics’ value drivers and gaps with a concise, editable business model snapshot.
Reference Sources
Provides a credible source trail for Coya Therapeutics, Inc., making key assumptions easier to verify and decisions faster to defend.
Activities
Treg-focused therapeutic research
Coya Therapeutics, Inc. runs daily Treg-focused research to fine-tune regulatory T cell function across biologics, exosomes, and autologous cell therapy. That makes immunology and translational work core activities, with 1 clinical-stage platform aimed at advancing immune modulation from lab data into human studies.
Clinical development in ALS and FTD
COYA 101 is already in Phase 2a for ALS, while COYA 301 is being advanced for frontotemporal dementia. Clinical development drives Company Name’s value creation through protocol design, site activation, enrollment, and safety follow-up across these programs.
IND-enabling work for COYA 301 and 302
COYA Therapeutics, Inc. is focused on IND-enabling work for 2 lead programs, COYA 301 and COYA 302, moving them toward clinic-ready assets. That means completing preclinical packages, CMC readiness, toxicology, and FDA-ready regulatory documents so the company can file IND applications and advance both assets into first-in-human development.
Preclinical discovery for COYA 201 and 206
Preclinical discovery for COYA 201 and COYA 206 is the early R&D engine behind Coya Therapeutics, Inc.'s exosome platform: COYA 201 is an allogeneic exosome candidate, and COYA 206 is an antigen-directed exosome program. Both are still in discovery, so the work centers on target validation and translational studies before clinical entry.
- 2 early-stage exosome programs
- Discovery and target validation
- Translational experiments before clinic
- Expands beyond lead clinical assets
Manufacturing and quality control
Coya Therapeutics, Inc. must run tight manufacturing and quality control for cell and exosome therapies, where every lot needs process checks and release tests before use. Autologous, allogeneic, and biologic formats each drive different CMC demands, so strong quality systems are what keep results reproducible, safe, and regulator-ready.
- Tight process control
- Batch release testing
- Format-specific CMC needs
- Safety and reproducibility
- Regulatory acceptance
Coya Therapeutics: 1 Clinical Asset, 2 Exosome Programs
Coya Therapeutics, Inc. focuses on Treg biology, with 1 Phase 2a clinical asset and 2 exosome programs in discovery. Its key work is translational R&D, IND-enabling studies, clinical execution, and CMC control for cell and exosome therapies.
| Activity | Count |
|---|---|
| Clinical-stage programs | 1 |
| Discovery exosome programs | 2 |
| Core workstreams | 4 |
Delivered as Displayed
Business Model Canvas
This Coya Therapeutics, Inc. Business Model Canvas preview is the exact document you will receive after purchase, not a sample or placeholder. What you see here is a direct snapshot of the final file, with the same structure, content, and formatting. Once your order is complete, you’ll get full access to this same ready-to-use document.
Resources
COYA 101 Phase 2a data
COYA 101’s completed Phase 2a ALS study is a core asset: the trial enrolled 12 patients and gave Coya Therapeutics, Inc. human data on safety, dosing, and early biologic activity. That readout strengthens pipeline credibility and gives the Company a concrete package for future partnering talks and follow-on development.
Treg-modulating platform knowledge
Coya Therapeutics, Inc. key resource is its Treg-modulating know-how: deep expertise in regulatory T cells, immune balance, and how to turn that science into biologics, exosomes, and cell therapies. This platform is the company’s main intellectual engine and underpins its pipeline and future development work.
Pipeline assets 301 302 201 206
Coya Therapeutics, Inc. has one clinical-stage asset, two IND-track programs, and two earlier discovery or preclinical programs, giving it a five-asset pipeline across neurological, autoimmune, and metabolic indications. That breadth is a key resource: it spreads risk, supports pipeline optionality, and gives Company Name multiple shots at near- and mid-term value creation.
Specialized scientific and clinical talent
Coya Therapeutics, Inc. depends on specialized scientific and clinical talent because Treg-based therapy needs immunology, neurology, cell therapy, and regulatory skill in one team. In FY2025, that mix is still the core resource for moving from preclinical work into human trials, where one weak step can slow the whole program.
- Immunology and neurology know-how
- Cell therapy development skill
- Clinical trial execution
- Regulatory strategy support
Houston headquarters and operating infrastructure
Coya Therapeutics, Inc. is based in Houston, Texas, and that single site anchors corporate management, scientific oversight, and investor communications. For a public biotech, the key operating layer also covers 3 core control systems: compliance, finance, and governance.
- Houston HQ: 1 central base
- Supports management and science
- Handles investor communications
- Backs compliance, finance, governance
Coya’s Key Assets: 5-Asset Pipeline and Phase 2a ALS Data
Coya Therapeutics, Inc.'s key resources are its Treg-modulating IP and know-how, a 5-asset pipeline, and the completed COYA 101 Phase 2a ALS data set. The study enrolled 12 patients, giving the Company human safety and biologic evidence to support future development.
| Resource | Data |
|---|---|
| Phase 2a ALS study | 12 patients |
| Pipeline | 5 assets |
| HQ | Houston, Texas |
Value Propositions
Treg-based disease modulation
Coya Therapeutics, Inc. uses therapies designed to fine-tune regulatory T cells, which make up about 5% to 10% of circulating CD4 T cells, to address upstream immune dysregulation rather than only ease symptoms. That makes the approach different from standard symptomatic care in neurology and autoimmunity, where the goal is usually to manage disease effects, not reset immune balance.
Potential in neurodegenerative disease
Coya Therapeutics, Inc. is targeting high-unmet-need diseases with COYA 401 in ALS, COYA 301 in frontotemporal dementia, and COYA 302 for neurodegenerative and autoimmune disorders. ALS affects about 30,000 Americans, and the core value proposition is potential disease modification where current care still offers limited slowing of decline.
Multi-modality pipeline
Coya Therapeutics, Inc. uses 4 therapeutic formats: biologics, autologous Tregs, allogeneic exosomes, and antigen-directed exosomes. That multi-modality pipeline gives the Company multiple shots on goal across several diseases, so one program does not carry all the risk.
Clinical proof-of-concept from COYA 101
COYA 101 has already completed a Phase 2a ALS study, giving Coya Therapeutics, Inc. an early human proof-of-concept signal for its regulatory T-cell platform. In a small clinical readout, that kind of traction can lift confidence with investors, partners, and investigators more than preclinical data alone.
- Completed Phase 2a in ALS
- Early human signal for the platform
- Supports partner and investor confidence
Off-the-shelf and personalized options
COYA 101 is autologous, so it can support a personalized treatment path, while COYA 201 is built as an allogeneic exosome candidate, which points to broader scale and simpler manufacturing. That mix gives Coya Therapeutics, Inc. two value routes in one pipeline: precision for hard-to-treat patients and a more scalable option for future commercial rollout.
- COYA 101: personalized, autologous path.
- COYA 201: scalable, allogeneic exosome path.
- Two formats strengthen future positioning.
Coya Therapeutics: Immune Reset for ALS and Neuroinflammatory Disease
Coya Therapeutics, Inc. sells a disease-modifying immune-reset story: it tunes regulatory T cells, not just symptoms, in ALS and other high-need neuroinflammatory diseases. Its value is backed by early human proof in ALS and a multi-modality pipeline spanning biologics, autologous Tregs, and exosomes.
| Value point | Fact |
|---|---|
| Platform | Regulatory T-cell modulation |
| ALS need | About 30,000 Americans |
| Pipeline | COYA 401, 301, 302 |
Customer Relationships
Investigator-led clinical partnerships
In FY2025, Coya Therapeutics, Inc. relied on specialist physicians and site teams to keep investigator-led trials moving through screening, dosing, monitoring, and endpoint analysis. These ties are data-heavy and must stay active at every visit, because one missed assessment can weaken the whole dataset.
Scientific advisory engagement
Coya’s scientific advisory engagement matters because it works in a novel field of immune regulation and exosome biology, where expert input helps validate targets and sharpen trial design. That credibility also supports capital markets confidence, since scientific proof and development discipline can matter as much as the data itself.
Investor and shareholder communications
As a public biotech, Coya Therapeutics, Inc. must keep investors updated on strategy, pipeline progress, and clinical milestones through earnings calls and SEC filings; that steady flow of data helps preserve trust and support access to capital. Clear, timely updates matter even more when trial results and cash runway can move valuation fast.
Regulatory interaction management
Coya Therapeutics, Inc. needs tight regulator ties across IND prep, protocol talks, and safety reporting. The FDA’s IND safety report clock is 15 calendar days for most events, so disciplined updates help keep trials on track and reduce hold risk.
- IND filing discipline matters
- 15-day safety reporting window
- Protocol alignment keeps studies moving
Partner diligence and collaboration support
Coya Therapeutics, Inc. has to make partner diligence easy, because biotech deals often hinge on data rooms, slide decks, and technical reviews before any licensing, manufacturing, or research pact moves ahead. That matters for monetization: with 1 lead asset in ALS and a small public-market footprint, each credible collaboration can shape future cash flow and deal terms.
- Support fast data-room access.
- Prepare clear technical reviews.
- Manage partner trust closely.
Coya’s FY2025 Relationships Were Laser-Focused on One ALS Asset
In FY2025, Coya Therapeutics, Inc. kept customer ties centered on trial sites, specialist physicians, scientific advisers, investors, regulators, and partners. With 1 lead ALS asset, its relationships had to stay tight, data-driven, and fast-moving.
| Relationship | FY2025 data point |
|---|---|
| Regulators | 15-day IND safety report window |
| Pipeline | 1 lead asset in ALS |
Channels
Clinical trial sites
Specialist clinical trial sites are Coya Therapeutics, Inc.'s main channel for COYA 101, COYA 301, and COYA 302, linking the Company to physicians and patients with ALS, Alzheimer’s, and Parkinson’s profiles across 3 clinical programs. These sites also generate the real-world development data that drives safety, dosing, and efficacy decisions.
Scientific conferences and publications
Coya Therapeutics, Inc. uses peer-reviewed papers and conference talks to turn Treg platform data into credibility for clinicians, scientists, and investors. This is vital for novel exosome work, where peer review and live readouts often carry more weight than direct sales.
Investor relations materials
Investor relations materials are Coya Therapeutics, Inc.'s main channel, with public filings, earnings materials, and corporate presentations turning pipeline updates into market context. As a pre-commercial Company Name, it still had "0" product revenue, so these disclosures are critical for explaining clinical progress, cash use, and next steps.
Business development outreach
Business development outreach helps potential partners discover Coya Therapeutics’ platform through direct contact and corporate networking, and it can lead to licensing, co-development, and manufacturing talks. For a clinical-stage biotech, this channel is a key non-dilutive path, since deal value can come from upfront fees, milestones, and royalties instead of new share issuance.
- Drives partner-led deal flow
- Supports licensing and co-development
- Can create non-dilutive value
Regulatory submission pathway
IND applications are Coya Therapeutics, Inc.’s formal gate into human studies, turning preclinical and CMC packages into FDA-authorized testing. This channel is critical for COYA 301 and COYA 302, which depend on regulatory clearance before first-in-patient dosing.
As of 2025 filings, Coya Therapeutics, Inc. remained a clinical-stage company with no product revenue, so IND timing directly affects spend, milestones, and trial starts.
- IND = first human-testing step
- Converts lab work into clinic access
- Key for COYA 301 and COYA 302
- Drives timing, cost, and risk
Coya’s Growth Runs Through Trial Sites, IR, and Partner Outreach
Coya Therapeutics, Inc. reaches patients mainly through specialist clinical trial sites, plus scientific publications, conference talks, investor materials, and business development outreach. In 2025 filings, the Company still reported $0 product revenue, so these channels are the main way it moves COYA 101, COYA 301, and COYA 302 from data to demand.
| Channel | Role | 2025 data |
|---|---|---|
| Trial sites | Patient access | 3 programs |
| IR filings | Market updates | $0 revenue |
| BD outreach | Partner leads | Non-dilutive path |
Customer Segments
ALS patients and neurology specialists
COYA 101 has already been evaluated in ALS, so Coya Therapeutics, Inc. is focused near term on ALS patients and the neurologists who treat them. This segment matters because ALS still has a median survival of about 2 to 5 years after symptom onset, and only a few disease-modifying options exist, leaving a large unmet need.
Frontotemporal dementia stakeholders
COYA 301 targets frontotemporal dementia, a rare, high-unmet-need disease that often starts before age 65; U.S. estimates put FTD at about 50,000-60,000 people. The customer ecosystem includes patients, caregivers, and dementia specialists, who need better options for behavior, function, and daily care.
Neurodegenerative and autoimmune disease communities
Neurodegenerative and autoimmune disease communities are a large pool for Coya Therapeutics, Inc.: Parkinson’s disease affects about 1 million people in the U.S., ALS about 30,000, and autoimmune diseases more than 50 million Americans. COYA 302 is built for these disorders, so it can reach multiple indications and physicians looking for immune-modulating options.
Biopharma licensing partners
Biopharma licensing partners are key for Coya Therapeutics, Inc. because it is still clinical-stage, so value may come from licensing, co-development, or acquisition rather than direct drug sales. For large pharma, this fits a model where late-stage assets and platform programs can be bought or partnered before full commercialization.
- Clinical-stage company
- Targets pharma licensing deals
- Can support acquisition value
Capital providers and public investors
Coya Therapeutics, Inc. is still pre-commercial, so capital providers and public investors are the key economic customer segment that funds R&D, clinical trials, and corporate ops; there is no commercial revenue yet, so outside capital is essential. In a pre-revenue biotech model, their cash support is what keeps the pipeline moving toward value-creating milestones.
Pre-commercial, so funding is vital
Public capital backs R&D and trials
Investors fund operations before revenue
Coya’s Target Customers: Patients, Physicians, Partners, and Investors
Coya Therapeutics, Inc. serves ALS, FTD, and other neuroinflammation patients through neurologists and dementia specialists, plus caregivers and trial sites. It is still pre-commercial, so biopharma partners and capital markets are also core customer segments; Coya Therapeutics, Inc. had $0 product revenue and $71.7M cash and equivalents at 2025 year-end.
| Segment | Why it matters |
|---|---|
| ALS and FTD patients | High unmet need |
| Physicians and caregivers | Treatment access |
| Pharma and investors | Funding and exit path |
Cost Structure
Research and development spend
Research and development was Coya Therapeutics, Inc.'s main cost center, with FY2025 R&D near $18 million, reflecting discovery work, translational studies, and candidate optimization. As a clinical-stage biotech with a multi-asset pipeline, Coya Therapeutics, Inc. keeps R&D structurally high, and that spend will stay tied to trial progress and pipeline breadth.
Clinical trial costs
Clinical trial costs are a major driver for Coya Therapeutics, Inc., because Phase 2a ALS work and follow-on FTD studies require site fees, patient monitoring, data management, and statistical analysis. Human trials are among the priciest inputs in biotech, with Phase 2 programs often running into the high single-digit millions per study.
Manufacturing and CMC expenses
Manufacturing and CMC expenses are a core cash burn item for Coya Therapeutics, Inc. because cell therapy and biologics programs need process development, QC release testing, and GMP systems; autologous and exosome work each needs specialized manufacturing support. In Coya Therapeutics, Inc.'s latest 2025 filings, this spending sat inside R&D and directly pressured operating cash flow.
Regulatory and legal costs
Coya Therapeutics, Inc. carries recurring regulatory and legal spend for IND work, FDA-facing compliance, and patent filings. As a public biotech, it also absorbs SEC reporting and disclosure costs, so these overheads are built into the model and do not scale away with lower sales.
- IND prep and compliance are fixed biotech costs
- Patent work protects pipeline value
- SEC reporting adds steady overhead
General and administrative overhead
Coya Therapeutics, Inc. runs a Houston headquarters that must cover finance, HR, governance, and investor relations, even before product sales start. As a public biotech, its G&A stays fixed during long development cycles, so these overheads help keep the Company operating while it funds research and clinical work.
- Supports core back-office functions.
- Continues before product launch.
- Funds long development timelines.
Coya Therapeutics: R&D Drives FY2025 Costs
Cost Structure at Coya Therapeutics, Inc. is dominated by R&D, at about $18 million in FY2025, with clinical trials, CMC work, and pipeline optimization driving most spend. G&A, regulatory, and legal costs stay fixed while the Company funds long development cycles.
| Cost item | FY2025 |
|---|---|
| R&D | $18 million |
| Clinical/CMC/regulatory | Inside R&D |
| G&A | Fixed overhead |
Revenue Streams
No approved product sales yet
As of July 2026, Coya Therapeutics, Inc. remains clinical-stage, so it has no approved product sales and no recurring commercial drug revenue. That leaves near-term cash generation limited, with funding still tied mainly to equity raises, grants, or partnerships rather than product sales.
Upfront licensing fees
Coya Therapeutics, Inc. could turn its Treg platform into immediate cash through upfront licensing fees, a standard feature in biotech partnering deals. This is a plausible way to monetize the pipeline before later milestones or royalties, and it can help fund development without waiting for product sales.
Development milestone payments
Development milestone payments can add non-dilutive cash when Coya Therapeutics, Inc. hits IND filings, trial starts, or readouts in COYA 301, COYA 302, and later programs. That matters because each step can trigger partner funding before full commercialization, reducing reliance on equity and helping advance assets with less dilution risk.
Commercial royalties
Commercial royalties could become a long-term, high-margin revenue stream for Company Name if partnered assets clear approval and reach sales. In biotech licensing, royalty rates often sit in the 5% to 15% range of net sales, but the cash flow depends on downstream FDA success, launch timing, and market uptake.
- Long-term upside if assets are approved
- Typical biotech royalties: 5%–15%
- Revenue depends on sales and regulation
Future product sales
Coya Therapeutics, Inc. has no current product-sales revenue; this stream would only start if its own biologics, exosomes, or cell therapies clear approval and reach market. Until then, future product sales remain a stage-ahead revenue source, not an operating one.
- Direct sales begin only after approval
- Applies to biologics, exosomes, cell therapies
- Revenue is not current yet
Coya’s Near-Term Revenue Hinges on Licensing, Not Product Sales
Coya Therapeutics, Inc. has no 2026 product-sales revenue, so near-term income still depends on upfront licensing fees, development milestones, and later royalties. If partnered assets reach market, royalty rates in biotech often run 5%–15% of net sales, while direct product sales stay zero until approval.
| Stream | Status | Value |
|---|---|---|
| Product sales | None | Post-approval only |
| Licensing | Possible | Upfront cash |
| Royalties | Long term | 5%–15% |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.